Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups

Combined use of MammaPrint and a molecular subtyping profile (BluePrint) identifies disease subgroups with marked differences in long-term outcome and response to neo-adjuvant therapy. The aim of this study was to evaluate the prognostic value of molecular subtyping using MammaPrint and BluePrint in...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Katharine, Goldschmidt, Robert, Turk, Mary, Wesseling, Jelle, Stork-Sloots, Lisette, de Snoo, Femke, Cristofanilli, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621695/
https://www.ncbi.nlm.nih.gov/pubmed/26424167
http://dx.doi.org/10.1007/s10549-015-3587-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621695/
https://www.ncbi.nlm.nih.gov/pubmed/26424167
http://dx.doi.org/10.1007/s10549-015-3587-9

Ejemplares similares